The study, published April 2 in Journal of Clinical Oncology, obtained data from the Commission of Cancer programs, which represents more than 70% of all cancer cases diagnosed in the nation each year. The patient data was collected between 2013 and 2017.
The study found patient participation rates in cancer treatment trials was 7.1%, more than two times higher than historical estimates. Here are three other findings:
- Treatment trial enrollment was 21.6% at National Cancer Institute-designated comprehensive cancer centers, 5.4% at academic comprehensive cancer programs, 5.7% at integrated network cancer programs and 4.1% at community programs.
- Nearly 22% of patients participated in one or more cancer clinical research studies.
- Cancer patients participated in a variety of studies, including biorepository (12.9%), registry (7.3%), genetic (3.6%), QOL (2.8%), diagnostic (2.5%) and economic (2.4%) studies.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
